Fortis Medical Devices Teoranta — SEC Form D Filing

Fortis Medical Devices Teoranta filed an SEC Form D on August 10, 2026, reporting $450K raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
August 10, 2026
Amount reported
$450K
Industry
Medical Devices
Website
https://www.fortismd.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: IRELAND

Problem

Parkinson's Disease affects over 10 million people worldwide, with Freezing of Gait (FoG) impacting nearly 50% of these individuals, leading to falls, injuries, loss of independence, and a significant burden on patients, caregivers, and the healthcare system.

Solution

Fortis Medical Devices is developing cueStim, a non-invasive, FDA Class II De Novo medical device intended to reduce the number and severity of Freezing of Gait (FoG) events in Parkinson's patients by dynamically sensing movement and delivering patient-specific electrical stimulation.

Why now

The global treatment sales for Parkinson's Disease are projected to exceed $12 billion by 2030, and the healthcare costs associated with adult falls in the US are over $50 billion annually, indicating a significant and growing market need for effective solutions.

Verdict

Investors backed this round for its clear articulation of an unmet clinical need within a large patient population, rather than for a de-risked technology. The implicit bet was on the company's ability to navigate the complex regulatory pathway for a novel Class II device, and to demonstrate clinical efficacy that could drive adoption. Upside was limited by the significant capital and time required for clinical trials and regulatory approval before any commercial traction could be expected, making it a longer-term, higher-risk play compared to, for example, a B2B SaaS solution with immediate revenue potential.

Source: SEC EDGAR Form D filing